AU2016348418B8 - Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same - Google Patents

Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same Download PDF

Info

Publication number
AU2016348418B8
AU2016348418B8 AU2016348418A AU2016348418A AU2016348418B8 AU 2016348418 B8 AU2016348418 B8 AU 2016348418B8 AU 2016348418 A AU2016348418 A AU 2016348418A AU 2016348418 A AU2016348418 A AU 2016348418A AU 2016348418 B8 AU2016348418 B8 AU 2016348418B8
Authority
AU
Australia
Prior art keywords
subject
antibody
corticosteroid
uveitis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016348418A
Other languages
English (en)
Other versions
AU2016348418A8 (en
AU2016348418A1 (en
AU2016348418B2 (en
Inventor
Ronald BUGGAGE
Karen W. Chu
Valerle CORP DIT GENTI
Kristine A. Erickson
Dominique MERY-MIGNARD
Preethi Aavali Sridhara Sundaram
Rafael VARONA
Robert L. Vitti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2016348418A1 publication Critical patent/AU2016348418A1/en
Priority to AU2023233110A priority Critical patent/AU2023233110A1/en
Publication of AU2016348418B2 publication Critical patent/AU2016348418B2/en
Application granted granted Critical
Publication of AU2016348418A8 publication Critical patent/AU2016348418A8/en
Publication of AU2016348418B8 publication Critical patent/AU2016348418B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016348418A 2015-11-03 2016-11-03 Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same Active AU2016348418B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023233110A AU2023233110A1 (en) 2015-11-03 2023-09-20 Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250269P 2015-11-03 2015-11-03
US62/250,269 2015-11-03
EP16306166 2016-09-14
EP16306166.6 2016-09-14
US201662408391P 2016-10-14 2016-10-14
US62/408,391 2016-10-14
PCT/US2016/060344 WO2017079443A1 (en) 2015-11-03 2016-11-03 Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023233110A Division AU2023233110A1 (en) 2015-11-03 2023-09-20 Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

Publications (4)

Publication Number Publication Date
AU2016348418A1 AU2016348418A1 (en) 2018-06-21
AU2016348418B2 AU2016348418B2 (en) 2023-10-12
AU2016348418A8 AU2016348418A8 (en) 2023-10-19
AU2016348418B8 true AU2016348418B8 (en) 2023-10-19

Family

ID=57018106

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016348418A Active AU2016348418B8 (en) 2015-11-03 2016-11-03 Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
AU2023233110A Pending AU2023233110A1 (en) 2015-11-03 2023-09-20 Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023233110A Pending AU2023233110A1 (en) 2015-11-03 2023-09-20 Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

Country Status (13)

Country Link
US (2) US10968278B2 (https=)
EP (1) EP3371224B1 (https=)
JP (4) JP7272794B2 (https=)
KR (2) KR20260036589A (https=)
CN (1) CN108473583A (https=)
AU (2) AU2016348418B8 (https=)
BR (1) BR112018008900A8 (https=)
CA (1) CA3003874A1 (https=)
IL (1) IL319993A (https=)
MX (2) MX2018005589A (https=)
SG (1) SG11201803654TA (https=)
TW (3) TW202339795A (https=)
WO (1) WO2017079443A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
IL319993A (en) * 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
AU2019329958B2 (en) 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
CN116528892A (zh) * 2020-10-28 2023-08-01 再生生物股份有限公司 用于眼部适应症的载体化抗TNF-α抗体
AU2023369998A1 (en) * 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
WO2009140348A2 (en) * 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠＬ-1β 관련 병태의 치료 방법
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014352801B2 (en) 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis", NCT01900431 ON 2015_04_13: CLINICALTRIALS.GOV ARCHIVE:, 13 April 2015 (2015-04-13), XP055348421, Retrieved from the Internet [retrieved on 20170222] *
PHOEBE LIN: "Targeting interleukin-6 for noninfectious uveitis", CLINICAL OPHTHALMOLOGY, 1 September 2015 (2015-09-01), pages 1697, XP055348429, DOI: 10.2147/OPTH.S68595 *
QUAN DONG NGUYEN: "The SATURN Study (SARIL-NIU): Sarilumab for the Treatment of Posterior Segment Non-Infectious Uveitis (NIU)", INVEST. OPHTHALMOL. VIS. SCI., vol. 56, no. 7, 1 July 2015 (2015-07-01), pages 3116, XP055348978 *

Also Published As

Publication number Publication date
WO2017079443A1 (en) 2017-05-11
US20170166646A1 (en) 2017-06-15
EP3371224A1 (en) 2018-09-12
JP2021193120A (ja) 2021-12-23
BR112018008900A8 (pt) 2019-02-26
CN108473583A (zh) 2018-08-31
WO2017079443A8 (en) 2017-07-06
JP7272794B2 (ja) 2023-05-12
KR20260036589A (ko) 2026-03-17
AU2016348418A8 (en) 2023-10-19
IL319993A (en) 2025-06-01
TWI786636B (zh) 2022-12-11
MX2022011972A (es) 2022-10-20
BR112018008900A2 (pt) 2018-11-06
US10968278B2 (en) 2021-04-06
TW201729828A (zh) 2017-09-01
TW202138001A (zh) 2021-10-16
EP3371224B1 (en) 2026-04-29
AU2016348418A1 (en) 2018-06-21
US20210301027A1 (en) 2021-09-30
AU2016348418B2 (en) 2023-10-12
AU2023233110A1 (en) 2023-10-05
TW202339795A (zh) 2023-10-16
SG11201803654TA (en) 2018-05-30
KR102930886B1 (ko) 2026-02-25
JP2023062062A (ja) 2023-05-02
CA3003874A1 (en) 2017-05-11
JP7581399B2 (ja) 2024-11-12
TWI729022B (zh) 2021-06-01
MX2018005589A (es) 2018-11-09
KR20180073680A (ko) 2018-07-02
JP2025020227A (ja) 2025-02-12
JP2018532804A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
AU2016348418B8 (en) Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same
EP3703818B1 (en) Il-4r antagonist for use in a method for treating or preventing asthma
CN107073110A (zh) 使用il‑17拮抗剂抑制银屑病关节炎患者的结构损伤进展
JP2025134086A (ja) 関節リウマチを有する対象における疼痛を治療するための組成物および方法
JP2026032195A (ja) 関節リウマチのための皮下トシリズマブの改良された投薬量
TW202432598A (zh) 藉由投予il-4r拮抗劑治療手足皮膚炎的方法
WO2019232528A1 (en) Dosing of a bispecific antibody that bind cd123 and cd3
RU2747193C2 (ru) Композиции, содержащие антитела к il6r, для лечения увеита и макулярного отека, и способы их применения
HK40107894A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
TW202608479A (zh) 治療具有類風濕性關節炎的個體中疼痛之組成物及方法
HK40036672A (en) Il-4r antagonist for use in a method for treating or preventing asthma
HK40036672B (en) Il-4r antagonist for use in a method for treating or preventing asthma

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 23 , PAGE(S) 3352 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC., APPLICATION NO. 2016348418, UNDER INID (72) CORRECT THE CO-INVENTOR TO MERY-MIGNARD, DOMINIQUE

Free format text: IN VOL 57 , NO 40 , PAGE(S) 5858 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC., APPLICATION NO. 2016348418, UNDER INID (72) CORRECT THE CO-INVENTOR MERY-MIGNARD, DOMINIQUE

FGA Letters patent sealed or granted (standard patent)